Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Full Chrome Therapeutics fourth quarter and full year 2024 financial results and business update conference call. Currently all participants are in listen-only mode. This call is being webcast live and can be accessed on the investor section of Full Chrome's website at www.fullchrometx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995, may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future because not taking on and any applications to do so. These refer to Wilkrom's most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Wilkrom. Joining Alex on the call are Alan Musil, Chief Financial Officer, and Dr. Ian Frazier, Senior Vice President of Early Development. After providing updates on the company's key programs, there will be a brief Q&A in which Alex, Allen and Ian will be available to answer your questions. With that, it's my pleasure to turn the call over to Alex. That's great. Thanks so much, Marvin. Good morning, everyone, and thank you for joining us today. The latter part of 2024 and early 2025 has been an exciting period for Fulcrum, with notable progress for our lead program, Pociridae, currently in development for the treatment of sickle cell disease. Wi...